

# Table of Contents

## Volume 1

### **CHAPTER 1. BIOTECHNOLOGY AND THE PATENT SYSTEM**

- § 1:1 “Biotechnology” and “Invention”
- § 1:2 —Isolated and mutated microorganisms
- § 1:3 —Genetically engineered organisms
- § 1:4 —Vaccines
- § 1:5 —Cell, tissue, and organ cultures
- § 1:6 —Hybrid cell cultures
- § 1:7 Trade secrets, patents, and the genetic engineering industry
- § 1:8 Fundamental patent law concepts

### **CHAPTER 2. PATENT ELIGIBILITY OF LIVING ORGANISMS PER SE**

- § 2:1 Patent eligibility (“statutory subject matter”)—  
Generally
- § 2:2 Patentability of living organisms: Early developments
- § 2:3 *Ex parte Chakrabarty*: Proceedings before the patent office
- § 2:4 *Ex parte Bergy*: Proceedings before the patent office
- § 2:5 The CCPA’s 1977 *Application of Bergy* decision (Bergy I)
- § 2:6 The CCPA’s 1978 *Chakrabarty* decision
- § 2:7 The CCPA’s consolidated 1979 decision on remand by the Supreme Court
- § 2:8 The Supreme Court’s *Chakrabarty* decision
- § 2:9 Flook and “unforeseen technologies”
- § 2:10 The import of the Plant Patent Act
- § 2:11 Static v. Dynamic Construction
- § 2:12 “Life form” patents and human society
- § 2:13 Vitalism
- § 2:14 Human organisms

### **CHAPTER 3. FURTHER CONSIDERATION OF JUDICIAL EXCEPTIONS TO PATENT ELIGIBILITY**

- § 3:1 Overview

- § 3:2 Supreme Court decisions
- § 3:3 Patent eligibility in lower courts
- § 3:4 Living organisms
- § 3:5 Nonliving microbiological products
- § 3:6 DNA and RNA
- § 3:7 Peptides and proteins (including antibodies)
- § 3:8 Other biochemicals
- § 3:9 Other chemicals
- § 3:10 Fermentation processes
- § 3:11 Diagnostic methods
- § 3:12 Non-Fermentation processes relating to cells in vitro
- § 3:13 Treatment methods
- § 3:14 Processes involving mental, mathematical, or computer-implemented steps
- § 3:15 Printed matter
- § 3:16 Miscellaneous
- § 3:17 PTO Guidelines
- § 3:18 Patent process eligibility: miscellaneous

## **CHAPTER 4. NOVELTY, NONOBVIOUSNESS, AND DOUBLE PATENTING**

### **I. INTRODUCTION**

- § 4:1 Generally
- § 4:2 Under the 1952 Patent Act
- § 4:3 Under Pre-AIA revisions to the 1952 Patent Act
- § 4:4 Under the 2011 America Invents Act (AIA)

### **II. STANDARD OF NOVELTY**

- § 4:5 Generally
- § 4:6 Novelty issues in biotechnology and selected chemical cases
- § 4:7 Classical microbiology and cell biology novelty cases
- § 4:8 Molecular biology and protein chemistry novelty cases
- § 4:9 Immunology novelty cases
- § 4:10 Miscellaneous biotechnology novelty cases
- § 4:11 Selected pharmaceutical and medical device novelty cases

### **III. STANDARD OF NONOBVIOUSNESS**

#### **A. IN GENERAL**

- § 4:12 Generally
- § 4:13 Development of the pre-*KSR* teaching-suggestion-motivation test

## TABLE OF CONTENTS

- § 4:14 Generally—Effect of *KSR* on obviousness analysis
- § 4:15 —Prima facie obviousness—Structural similarities of chemical compounds
- § 4:16 — —Motivation and utility
- § 4:17 — —Recognition of the problem
- § 4:18 — —Means of achieving the result
- § 4:19 — —Expectation of success
- § 4:20 — —Effect of negative teachings on expectations
- § 4:21 — —Unrealistic expectations of success
- § 4:22 — —Competing approaches
- § 4:23 —“Unexpected results”
- § 4:24 —“Secondary considerations”

## B. APPLICATION IN PARTICULAR SITUATIONS

- § 4:25 Processes
- § 4:26 Statutory limitation on obviousness of Biotechnological processes (Pre-AIA)
- § 4:27 Effect of AIA
- § 4:28 Classical microbiology and cell biology cases
- § 4:29 Classical immunology cases
- § 4:30 Molecular biology cases
- § 4:31 Obviousness/Molecular Biology
- § 4:32 Molecular immunology cases
- § 4:33 Miscellaneous biotechnology cases
- § 4:34 Selected pharmaceutical and medical device cases
- § 4:35 Miscellaneous Chemical Cases

## IV. PRIOR ART: COMMON ISSUES

- § 4:36 Generally
- § 4:37 Theory of the “inventorship entity”
- § 4:38 Under the 1952 Patent Act
- § 4:39 Under the 2011 America Invents Act
- § 4:40 State of the art date
- § 4:41 —Date of the invention (Pre-AIA)
- § 4:42 —“Critical date” (Pre-AIA)
- § 4:43 —Effective filing date
- § 4:44 Intervening art

## V. DOCUMENTARY PRIOR ART

- § 4:45 “Enabling” character
- § 4:46 “Printed publications”
- § 4:47 “Printed Publications”—Seminars, conferences, trade shows and other meetings
- § 4:48 “Printed publications”—Library collections
- § 4:49 —Confidential and secret documents

- § 4:50 —Electronic publications
- § 4:51 U.S. patents and applications: pre-2000 practice
- § 4:52 U.S. patents and applications: effect of the 1999 Patent Act and 2002 amendments
- § 4:53 U.S. patents and applications: effect of the 2011 America Invents Act

## **VI. NONDOCUMENTARY PRIOR ART**

### **A. IN GENERAL; PRIOR USE AND SALE**

- § 4:54 Generally
- § 4:55 Prior use and sale

### **B. PRIOR INVENTION OF ANOTHER (PRE-AIA)**

- § 4:56 Generally
- § 4:57 Constructive Reduction to Practice
- § 4:58 Actual Reduction to Practice, Generally
- § 4:59 Reduction to practice—Animal versus clinical testing
- § 4:60 —Released microorganisms: laboratory versus field testing
- § 4:61 —Early vaccine cases
- § 4:62 Conception
- § 4:63 Diligence
- § 4:64 Appreciation
- § 4:65 Abandonment, suppression, or concealment
- § 4:66 Prior invention as a defense

### **C. KNOWLEDGE AND SUGGESTIONS OF OTHERS**

- § 4:67 Knowledge of others (Pre-AIA)
- § 4:68 Suggestions of others

## **VII. DOUBLE PATENTING; STATUTORY LIMITATIONS ON OBVIOUSNESS**

- § 4:69 Double patenting
- § 4:70 Limitations on obviousness

## **VIII. OTHER CONSIDERATIONS**

- § 4:71 The impact of Artificial Intelligence

## **CHAPTER 5. DISCLOSURE REQUIREMENTS**

### **I. OVERVIEW OF DISCLOSURE REQUIREMENTS**

- § 5:1 Generally

TABLE OF CONTENTS

**II. DESCRIPTION REQUIREMENT**

- § 5:2 Generally
- § 5:3 “Heightened” written description
- § 5:4 1998 Interim guidelines
- § 5:5 1999 Revised interim guidelines
- § 5:6 2001 Revised written description guidelines
- § 5:7 Original (2000) Written Description Training Materials
- § 5:8 2008 Written Description Training Materials
- § 5:9 Biotechnology cases
- § 5:10 —Classical microbiology and cell biology cases
- § 5:11 —Immunology cases
- § 5:12 —Molecular biology cases
- § 5:13 —Miscellaneous biotechnology cases

**III. UTILITY AND RELATED ENABLEMENT REQUIREMENTS**

**A. IN GENERAL**

- § 5:14 Introduction
- § 5:15 Utility: benefit to society
- § 5:16 Asserted or well-established utility
- § 5:17 Specific and substantial utility

**B. OPERABILITY AS A REQUIREMENT FOR UTILITY**

- § 5:18 Generally
- § 5:19 The presumption of utility and establishment of a *prima facie* case of inoperability
- § 5:20 The standard of proof of operability: Credibility
- § 5:21 Evidence of therapeutic utility: Human clinical data
- § 5:22 Evidence of human therapeutic utility: Animal data
- § 5:23 Animal data as proof of veterinary utility
- § 5:24 Evidence of human therapeutic utility: In vitro data

**C. UTILITY AND INJURIOUS INVENTIONS**

- § 5:25 Inventions contrary to public policy, generally
- § 5:26 Unsafe Inventions
- § 5:27 Utility and Related Enablement Issues
  - Biotechnology Cases

**D. OPERABILITY AND REDUCTION TO PRACTICE**

- § 5:28 Utility as a reduction to practice issue

#### **IV. ENABLEMENT OF OPERABLE INVENTIONS**

##### **A. IN GENERAL**

- § 5:29 Generally
- § 5:30 Enablement

##### **B. BIOTECHNOLOGY CASES NOT RELATED TO DEPOSIT ISSUES**

- § 5:31 Classical microbiology and cell biology cases
- § 5:32 Classical immunology cases
- § 5:33 Molecular biology and protein chemistry cases
- § 5:34 Molecular immunology cases
- § 5:35 Miscellaneous biotechnology cases
- § 5:36 Selected pharmaceutical and medical device cases

#### **V. “BEST MODE” REQUIREMENT**

- § 5:37 Generally
- § 5:38 Biotechnology cases

#### **VI. DEPOSIT OF BIOLOGICAL MATERIALS AS A MEANS OF SUPPLEMENTING SPECIFICATION**

##### **A. OVERVIEW**

- § 5:39 Generally
- § 5:40 History
- § 5:41 Summary of deposit rules
- § 5:42 Summary of Budapest treaty

##### **B. WHEN IS A DEPOSIT REQUIRED TO SATISFY 35 U.S.C.A. § 112 ?**

- § 5:43 PTO rules and guidelines
- § 5:44 Isolates and mutants, generally
- § 5:45 Hybridoma cell lines
- § 5:46 Fully genotyped organisms
- § 5:47 Genetically engineered organisms

##### **C. WHEN MUST DEPOSIT BE MADE?**

- § 5:48 Pre- *Lundak* case law
- § 5:49 *Ex parte Lundak*
- § 5:50 *In re Lundak*
- § 5:51 Post- *Lundak* problems with postfiling deposits

TABLE OF CONTENTS

- D. HOW AND WHEN SHOULD DEPOSITED BIOLOGICAL MATERIAL BE DESCRIBED IN SPECIFICATION?
  - § 5:52 Generally
- E. DURING WHAT PERIOD MUST DEPOSIT BE MADE AVAILABLE TO PUBLIC?
  - § 5:53 Starting date
  - § 5:54 Term of availability
  - § 5:55 Post-issuance availability problems
- F. WHAT RESTRICTIONS MAY BE PLACED ON PUBLIC AVAILABILITY?
  - § 5:56 Generally
  - § 5:57 Under prior law
  - § 5:58 Under the Budapest treaty
  - § 5:59 Development of a new “restrictions on availability” policy
  - § 5:60 Lawful restrictions under final deposit rules
- G. HOW ARE VIABILITY AND OPERABILITY PROBLEMS TREATED?
  - § 5:61 Generally
- H. WHERE MAY DEPOSIT BE MADE?
  - § 5:62 Under prior law
  - § 5:63 Under the Budapest treaty
  - § 5:64 Under new deposit rules
- I. WHAT MUST BE DEPOSITED?
  - § 5:65 Generally
- J. WHAT IS THE RELATIONSHIP OF DEPOSITS TO OTHER REQUIREMENTS OF 35 U.S.C.A. § 112 ?
  - § 5:66 “Description”
- K. DEPOSITS UNDER TREATIES AND CONVENTIONS
  - § 5:67 Deposits under patent cooperation treaty
  - § 5:68 Deposits under european patent convention

L. PTO AUTHORITY TO REQUIRE SPECIMENS  
UNDER 35 U.S.C.A. § 114

§ 5:69 Generally

**VII. PREPARING THE SPECIFICATION**

§ 5:70 Generally

§ 5:71 Molecular biology cases

§ 5:72 Immunology cases

§ 5:73 Classical microbiology and cell biology cases

**VIII. SEQUENCE LISTINGS**

§ 5:74 Generally

§ 5:75 General information

§ 5:76 Sequence information

**CHAPTER 6. INFRINGEMENT**

**I. IN GENERAL**

§ 6:1 Introduction

§ 6:2 Claim construction and literal infringement

§ 6:3 Doctrine of equivalents

§ 6:4 Reverse doctrine of equivalents

**II. FILE WRAPPER ESTOPPEL**

§ 6:5 Generally

§ 6:6 Pre-*Festo* case law

§ 6:7 Effect of *Festo* decision

**III. CASE STUDIES OF CLAIM INTERPRETATION  
IN BIOTECHNOLOGY PATENT  
INFRINGEMENT LITIGATION**

§ 6:8 Classical biochemistry infringement cases

§ 6:9 Classical microbiology and cell biology infringement  
cases

§ 6:10 Classical immunology infringement cases

§ 6:11 Molecular biology infringement cases

§ 6:12 Molecular immunology infringement cases

§ 6:13 Miscellaneous biotechnology infringement cases

§ 6:14 Selected pharmaceutical and medical device  
infringement cases

**IV. DIRECT INFRINGEMENT**

§ 6:15 Generally

TABLE OF CONTENTS

- § 6:16 Product patents: coverage of new processes and uses
- § 6:17 Process patent infringement

**V. CONTRIBUTORY AND ACTIVE INDUCEMENT OF INFRINGEMENT**

- § 6:18 Contributory infringement
- § 6:19 Active inducement of infringement

**VI. TEMPORAL SCOPE OF U.S. PATENTS**

- § 6:20 Effect of the 1994 GATT implementing legislation
- § 6:21 Patent term adjustment
- § 6:22 Provisional rights
- § 6:23 Issuance and expiration issues generally
- § 6:24 Patent term extension
- § 6:25 Reissues and intervening rights

**VII. GEOGRAPHIC SCOPE OF U.S. PATENTS**

- § 6:26 Generally

**VIII. MISCELLANEOUS DEFENSES AND LIMITATIONS**

- § 6:27 The classic “experimental use” defense
- § 6:28 Pharmaceutical testing and the § 271(e)(1) defense
- § 6:29 Filing an ANDA, paper ANDA, or aPLA as an infringing act under § 271(e)(2)
- § 6:30 The “exhaustion” defense
- § 6:31 Prior activity-based personal defenses—First inventor defense (1999–2011)
- § 6:32 —Prior user defense under the America Invents Act
- § 6:33 Limitations on infringement of patents on medical and surgical procedures
- § 6:34 Federal authorization and consent

**IX. EFFECT OF PATENTS ON THE DRUG AND BIOLOGICAL PRODUCT APPROVAL PROCESS**

- § 6:35 On drug approval
- § 6:36 On Approval of biological products that are “Biosimilars”

**X. ENFORCEMENT OF PATENT RIGHTS BY THE INTERNATIONAL TRADE COMMISSION**

- § 6:37 Generally

**XI. PATENT ENFORCEMENT AND ANTITRUST**

- § 6:38 Generally

## **XII. MISCELLANEOUS INFRINGEMENT ISSUES**

- § 6:39 Contractor immunity under the Pandemic Readiness  
and Emergency Preparedness Act

## **CHAPTER 7. CLAIM DRAFTING**

### **I. LEGAL SIGNIFICANCE OF THE CLAIM AND THE ART OF CLAIM DRAFTING**

- § 7:1 Generally

### **II. THE “DEFINITENESS” REQUIREMENT**

- § 7:2 Generally  
§ 7:3 Terms of degree—Generally  
§ 7:4 —Taxonomic classification of organisms  
§ 7:5 Completeness  
§ 7:6 Biotechnology cases

### **III. PARTICULAR LIMITATIONS IN CLAIMS**

- § 7:7 Functional limitations in claims  
§ 7:8 Negative limitations in claims  
§ 7:9 “Wherein” limitations in process claims  
§ 7:10 Preamble limitations of claims  
§ 7:11 Miscellaneous claim construction

### **IV. SPECIAL CLAIM FORMATS**

- § 7:12 “Fingerprint” claims  
§ 7:13 “Product-by-process” claims  
§ 7:14 —Infringement  
§ 7:15 —Patentability  
§ 7:16 “Markush group” claims  
§ 7:17 “Jepson” claims

### **V. CLAIMING MOLECULAR BIOLOGY INVENTIONS**

- § 7:18 Generally  
§ 7:19 Identifying structural genes and their proteins  
§ 7:20 Genetic engineering methods  
§ 7:21 Ancillary biological materials

### **VI. CLAIMING IMMUNOLOGY INVENTIONS**

- § 7:22 Generally  
§ 7:23 Monoclonal antibodies

## TABLE OF CONTENTS

- § 7:24 Hybridoma cell lines
- § 7:25 Immunological methods
- § 7:26 Antigens and haptens
- § 7:27 Reagents and test kits

## **VII. CLAIMING CLASSICAL MICROBIOLOGY AND CELL BIOLOGY INVENTIONS**

- § 7:28 Fermentation methods—Introduction
- § 7:29 —Organisms employed
- § 7:30 —Nutrient media
- § 7:31 —Operating conditions
- § 7:32 —Supplementary protection
- § 7:33 Fermentation products
- § 7:34 Isolation and cultivation methods
- § 7:35 Pure cultures of microbial isolates
- § 7:36 Mixed cultures and their use
- § 7:37 “Organism-plus-carrier” claims
- § 7:38 Mutation and breeding methods
- § 7:39 Mutant microorganisms
- § 7:40 Untransformed eukaryotic cell cultures
- § 7:41 Tissue and organ cultures, and their use

## **CHAPTER 8. PROCEDURE AND PRACTICE IN THE USPTO**

### **I. OVERVIEW**

- § 8:1 Generally

### **II. DRAFTING CONSIDERATIONS**

#### **A. IN GENERAL**

- § 8:2 Introduction
- § 8:3 Mention of government support

#### **B. COMPLIANCE WITH SEQUENCE LISTING RULES**

- § 8:4 Rationale and historical overview
- § 8:4.10 1990 sequence listing rules
- § 8:4.20 1998 sequence listing rules
- § 8:4.30 Compact disc regulations
- § 8:4.40 2021 amendments
- § 8:4.50 2022 transition to WIPO Standard ST.26
- § 8:5 Covered applications and sequences
- § 8:6 Sequence listing file format

- § 8:7 The general information part of the sequence listing XML
- § 8:8 The sequence data part of the sequence listing XML
- § 8:9 Sequence representation generally
- § 8:10 Nucleotide sequence representation
- § 8:11 Amino Acid sequence representation
- § 8:12 Discussion of selected feature keys
- § 8:13 Sequence listing XML file preparation
- § 8:14 Sequence listing XML file submission

### C. COMPLIANCE WITH DEPOSIT RULES

- § 8:15 Generally

### D. FORMAL DRAWINGS

- § 8:16 Generally
- § 8:17 Photographic figures
- § 8:18 Sequences as figures
- § 8:18.50 Prioritized examination

## III. PROSECUTION CONSIDERATIONS

- § 8:19 Petitions to make special
- § 8:20 Restriction
- § 8:21 —Independent inventions
- § 8:22 —Distinct inventions
- § 8:23 —Linking claims
- § 8:24 —Rejoinder of method claims to product claims
- § 8:25 —Genus and species
- § 8:26 —Post-GATT transitional restriction practice
- § 8:27 Compliance with Atomic Energy Act
- § 8:28 Suspension of prosecution
- § 8:29 Provisional applications—Original practice
- § 8:30 —Revised practice
- § 8:31 Standards of inequitable conduct
- § 8:31.50 Inequitable conduct in biotechnology cases
- § 8:32 Post-GATT transitional after final rejection practice
- § 8:33 Continued examination
- § 8:34 Domestic publication of foreign filed applications
- § 8:35 Post-AIPA Continuations
- § 8:36 Optional inter partes reexamination procedure
- § 8:37 Pre-AIA interference practice
- § 8:37.10 Section 135(b) requirements
- § 8:37.20 Corroboration
- § 8:37.30 Authentication
- § 8:37.40 Interference count

## TABLE OF CONTENTS

- § 8:38 Post-AIA derivation proceedings and derived patents suits
- § 8:39 Post-AIA supplemental examination
- § 8:40 Post-AIA post-grant review
- § 8:41 Post-AIA *inter partes* review

## **CHAPTER 9. UTILITY PATENT PROTECTION OF PLANT AND ANIMAL VARIETIES**

- § 9:1 Utility patent protection of plant varieties
- § 9:2 Utility patent protection of plant breeding and genetic engineering methods
- § 9:3 Utility patent protection of animal varieties—The constitutional mandate
- § 9:4 Drafting patent applications for animal varieties
- § 9:5 Design patent protection of ornamental features of animals and plants
- § 9:6 Protection of genetically engineered animals under european patents

## **CHAPTER 10. OWNERSHIP AND LICENSING**

### **I. INVENTORSHIP AND OWNERSHIP**

- § 10:1 Inventorship
- § 10:2 —Testing of compounds
- § 10:3 —Unexpected results
- § 10:4 —Contributions to “Written Description” or “Utility”
- § 10:5 —Particular cases
- § 10:6 —Correction of inventorship errors
- § 10:7 Express obligation to assign
- § 10:8 Implied obligation to assign—Employed to invent
- § 10:9 —Duty of loyalty
- § 10:10 —Shop rights license
- § 10:11 State statutes
- § 10:12 Federal statutes—Energy inventions
- § 10:13 —NASA-sponsored inventions
- § 10:14 —Other inventions made with government support
- § 10:15 —Inventions made by U.S. government employees
- § 10:16 Joint inventorship and ownership

### **II. LICENSING**

- § 10:17 Generally
- § 10:18 Advantages and disadvantages
- § 10:19 Timing

- § 10:20 Preparation for licensing—The licensor’s viewpoint
- § 10:21 —The licensee’s viewpoint
- § 10:22 Analyzing a license agreement
- § 10:23 The license grant—Types of licenses
- § 10:24 —Identifying the licensed rights
- § 10:25 Consideration
- § 10:26 —Running royalties
- § 10:27 —Minimum royalties
- § 10:28 —Milestone payments/timetables
- § 10:29 —Relaxation of payment obligations
- § 10:30 Termination
- § 10:31 Other common licensing provisions—Technical assistance and collaboration
- § 10:32 —Patent prosecution and maintenance
- § 10:33 —Extension of patent term
- § 10:34 —Duty of disclosure; Right of reference
- § 10:35 University licensing
- § 10:36 Federal licensing
- § 10:37 International licensing
- § 10:38 Antitrust considerations
- § 10:39 Biotechnology cases
- § 10:40 Implied license
- § 10:41 License to government

## Volume 2

### CHAPTER 11. PLANT PATENT PROTECTION

- § 11:1 Development and propagation of new plant varieties
- § 11:2 The Plant Patent Act
- § 11:3 Protected and unprotected “plants” under the Plant Patent Act —Bacteria
- § 11:4 —Tuber-propagated plants
- § 11:5 —Newly found plants versus newly created plants
- § 11:6 What is a variety
- § 11:7 A “novel” variety
- § 11:8 A “distinct” variety
- § 11:9 “Nonobvious” variety
- § 11:10 “Asexually reproduced” variety
- § 11:11 A variety found in a “cultivated state”
- § 11:12 Inventorship and ownership
- § 11:13 Conception and reduction to practice
- § 11:14 Disclosure requirements
- § 11:15 Claims for plant products
- § 11:16 Number and breadth of claims

## TABLE OF CONTENTS

- § 11:17 Plant patent infringement: Introduction
- § 11:18 Derivation as an element of infringement
- § 11:19 Distinctness and infringement
- § 11:20 Marking of protected varieties
- § 11:21 Active inducement and contributory infringement
- § 11:22 Plant patent term restoration
- § 11:23 Changes in plant patent protection under UPOV

## **CHAPTER 12. THE Plant Variety Protection Act and the UPOV**

- § 12:1 Obtaining protection under the Plant Variety Protection Act
- § 12:2 The scope of plant variety protection
- § 12:3 Application of the PVPA in the courts
- § 12:4 Activities of the plant variety protection office
- § 12:5 Comparison of the three avenues of plant variety protection
- § 12:6 Plant variety protection in UPOV countries

## **CHAPTER 13. PROTECTION OF BIOLOGICAL INVENTION ABROAD**

- § 13:1 Statutory protection in the Eastern Bloc
- § 13:2 Statutory protection in the Western Bloc
- § 13:3 Statutory protection in the Third World
- § 13:4 Plant patent protection outside of the conventions
- § 13:5 Judicial decisions relating to biological patent protection in the Federal Republic of Germany
- § 13:6 Judicial decisions relating to biological patent protection in the federal republic of germany—The “red dove” case
- § 13:7 —The “baker’s yeast” case
- § 13:8 —The “rose mutation” case
- § 13:9 —The “6-APA” case
- § 13:10 —The “antamanide” case
- § 13:11 Judicial decisions relating to biological patent protection in Great Britain—Microbiological processes and microorganisms are patentable; Other biological methods are not
- § 13:12 —Disclosure requirements
- § 13:13 Judicial decisions relating to biological patent protection in other “statute of monopolies” countries
- § 13:14 —Biological patent protection in New Zealand
- § 13:15 —Biological patent protection in Australia
- § 13:16 —Microbiological patent protection in Ireland
- § 13:17 —Microbiological patent protection in Canada
- § 13:18 Protection of biological invention in Japan

- § 13:19 Judicial decisions relating to biological patent protection in France

## **CHAPTER 14. OTHER FORMS OF PROTECTION FOR BIOTECHNOLOGY**

- § 14:1 Trade secret protection of cultures and “knowhow”
- § 14:2 Copyright protection not available for gene sequences or molecules
- § 14:3 —A DNA sequence is not a “work of authorship” within the meaning of the Copyright Act
- § 14:4 —A DNA sequence is neither an “original work” nor a “compilation”
- § 14:5 —The “discovery” of the functions of a novel DNA molecule cannot be appropriated by copyrighting the base sequence
- § 14:6 —The process by which a DNA molecule “expresses” a protein cannot be appropriated by copyrighting the base sequence which describes the process
- § 14:7 —Copyright protection does not extend to the utilization of the functional aspects of an article
- § 14:8 —The courts will be reluctant to confer the rights of a copyright owner upon the originator of a new nucleotide combination without a clear signal from congress
- § 14:9 —Nor can the originator of a novel gene sequence complain if another independently develops the same sequence
- § 14:10 Copyright protection for plant and animal phenotypes
- § 14:11 Tangible property rights in cell lines
- § 14:12 Exclusive drug approvals—Exclusivity of a full NDA holder under the Waxman-Hatch Act
- § 14:13 —Exclusivity of a full NADA holder under the Generic Animal Drug and Patent Term Restoration Act
- § 14:14 —Exclusivity of an ANDA applicant who challenges a patent
- § 14:15 —Exclusivity under the Orphan Drug Act
- § 14:16 Pediatric exclusivity
- § 14:17 Exclusivity under the Biologics Price Competition and Innovation Act (BPCIA)
- § 14:18 Contractual restrictions on tangible materials

## **APPENDIX A—UNITED STATES MATERIALS ON THE DEPOSIT OF MICROORGANISMS**

- APPENDIX A1. Manual of Patent Examining Procedure  
§ 608.01(p): Deposit of Microorganisms
- APPENDIX A1(1) Suggestion for Deposit of Biological Material

## TABLE OF CONTENTS

- APPENDIX A2. Rule on Deposit of Biological Materials for Patent Purposes, 37 C.F.R. §§ 1.801 to 1.809, effective January 1, 1990
- APPENDIX A2(1) PTO Draft Policy Statement on the Deposit of Biological Materials (1986)
- APPENDIX A2(2) PTO Advance Notice of Proposed Rulemaking on the Deposit of Biological Materials (June 19, 1987), 52 Fed. Reg. 34080 (Sept. 9, 1987) and 1080 Official Gazette 47 (Sept. 29, 1987)
- APPENDIX A2(3) PTO Notice of Proposed Rulemaking on Deposit of Biological Materials for Patent Purposes (Sept. 9, 1988), 53 Fed. Reg. 39420 (Oct. 6, 1988) and 1095 Official Gazette 47 (Oct. 25, 1988)
- APPENDIX A2(4) PTO Notice of Final Rule on Deposit of Biological Materials for Patent Purposes (July 21, 1989), 1106 Official Gazette 37 (Sept. 12, 1989)
- APPENDIX A3. PTO Notice on Designation of International Depositary Authorities Under the Budapest Treaty (July 14, 1978)
- APPENDIX A4. PTO Notice on Entry into Force of the Budapest Treaty (July 14, 1980)
- APPENDIX A5. PTO Notice on Request for Certification of Deposits Made Under the Budapest Treaty (Sept. 4, 1987)
- APPENDIX A6. PTO Rules and Regulations, Changes to the Time Period for Making any Necessary Deposit of Biological Material (April 27, 2001)
- APPENDIX A7. Rules on Applications as amended September 8, 2000

## **APPENDIX B—BUDAPEST TREATY MATERIALS ON DEPOSIT OF MICROORGANISMS**

- APPENDIX B1. Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure, effective August 19, 1980
- APPENDIX B2. Budapest Treaty Regulations, effective August 19, 1980, with Amendments effective January 31, 1981

- APPENDIX B3. Parties to the Treaty
- APPENDIX B4. International Depositary Authorities Under the Treaty

## **APPENDIX C—PATENT COOPERATION TREATY MATERIALS ON DEPOSIT OF MICROORGANISMS**

- APPENDIX C1. PCT Rule 13<sup>bis</sup>: Microbiological Inventions (effective January 31, 1981)
- APPENDIX C2. PCT Applicant's Guide, Annex M1: References to Deposits of Microorganisms
- APPENDIX C3. PCT Applicants' Guide, Annex M3, Form PCT/RO/134: Microorganisms
- APPENDIX C4. Information for PCT Applicants Designating the European Patent Organization, Official Journal 2/81 at 49–51

## **APPENDIX D—EUROPEAN PATENT CONVENTION MATERIALS ON DEPOSIT OF MICROORGANISMS**

- APPENDIX D1. Rule 28 (Original), effective October 7, 1977
- APPENDIX D2. Rule 28 (Amended), effective June 1, 1980
- APPENDIX D3. Rule 28a, effective June 1, 1980
- APPENDIX D4. European Patent Office Notice re European Patent Applications and European Patents in Which Reference Is Made to Microorganisms, Official Journal 8/86, July 8, 1986
- APPENDIX D5. European Patent Office Notice on Recognition of Microbiological Experts for the Purpose of EPC Rule 28, Official Journal 9/81

## **APPENDIX E**

APPENDIX E. *[Reserved]*

## **APPENDIX F—SEQUENCE LISTINGS**

- APPENDIX F1. Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821 to 1.825, effective October 1, 1990

TABLE OF CONTENTS

APPENDIX F1(1)	Draft Sequence Listing Rules (Sept. 23, 1988)
APPENDIX F1(2)	PTO Notice of Proposed Rulemaking (March 7, 1989): Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 54 Fed. Reg. 18671 (May 2, 1989), 1102 Official Gazette 34 (May 16, 1989)
APPENDIX F1(3)	PTO Notice of Final Rule (April 20, 1990): Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 55 Fed. Reg. 18,230 (May 1, 1990), 1114 Official Gazette 33 (May 15, 1990)
APPENDIX F1(4)	PTO Proposed Rules on Nucleotide and/or Amino Acid Sequence Listings (October 10, 1996)
APPENDIX F1(5)	PTO Rules and Regulations, Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Disclosures (June 1, 1998)
APPENDIX F1(6)	Requirements for Patent Applications Containing Sequence Disclosures, 37 C.F.R. §§ 1.821, 1.823–1.825, Effective December 18, 2000
APPENDIX F2.	1990 and 1998 Sequence Listing Rules
APPENDIX F2(1)	Covered Applications and Sequences
APPENDIX F2(2)	Overview of Requirements
APPENDIX F2(3)	Mandatory Components of the Sequence Listing: the “General Information” Header
APPENDIX F2(4)	Mandatory Components of the Sequence Listing: “Sequence Information”
APPENDIX F2(5)	Mandatory Components of the Sequence Listing: “Sequence Information”—Length
APPENDIX F2(6)	Mandatory Components of the Sequence Listing: “Sequence Information”—Type
APPENDIX F2(7)	Mandatory Components of the Sequence Listing: “Sequence Information”—Strandedness
APPENDIX F2(8)	Mandatory Components of the Sequence

- Listing: “Sequence Information”—  
Topology
- APPENDIX F2(9) Mandatory Components of the Sequence  
Listing: “Sequence Information”—  
Organism
- APPENDIX F2(10) Mandatory Components of the Sequence  
Listing: “Sequence Information”—  
Presentation of features
- APPENDIX F2(11) Enumeration of Amino Acid Sequences
- APPENDIX F2(12) Enumeration of Nucleic Acid Sequences
- APPENDIX F2(13) Formal Processing
- APPENDIX F3. Standard for Presentation of Nucleotide  
and Amino Acid Sequence Listings  
Using eXtensible Markup Language in  
Patent Applications
- APPENDIX F3(1) Adoption of Updated WIPO Standard  
ST.26; Revision to Incorporation by  
Reference

## **APPENDIX G—PLANT VARIETY PROTECTION MATERIALS**

- APPENDIX G1. United States Plant Variety Protection  
Act, 7 U.S.C. §§ 2321–2582 and  
Uncodified Sections
- APPENDIX G2. PVPA Regulations and Rules of Practice  
(Revised July 2013)
- APPENDIX G3(A) Guidelines Exhibit A: Origin and  
Breeding History
- APPENDIX G3(B) Guidelines Exhibit B: Statement of  
Distinctness
- APPENDIX G3(E) Guidelines Exhibit E: Statement of the  
Basis of Ownership
- APPENDIX G4. Application for Plant Variety Protection  
Certificate

## **APPENDIX H—MISCELLANEOUS U.S. MATERIALS**

- APPENDIX H1. PTO Notice, Microorganisms—Patentable  
Subject Matter (July 28, 1980)
- APPENDIX H2. Patentable Subject Matter—Living Subject  
Matter
- APPENDIX H3. PTO Notice, Plant Life—Patentable Subject  
Matter (October 8, 1985)

TABLE OF CONTENTS

APPENDIX H4.	PTO Notice, Animals—Patentability (April 7, 1987)
APPENDIX H5.	PTO Notice, Petitioning to Make Applications Relating to Biotechnology Special (June 22, 1988)
APPENDIX H6.	MPEP § 708.02, Petition to Make Special (Section VII, Inventions Relating to Recombinant DNA)
APPENDIX H7.	Background Information on Examining Tech Center 1600, Biotechnology
APPENDIX H8.	Biotechnology
APPENDIX H9.	Final PTO Utility Examination Guidelines
APPENDIX H10.	Proposed Utility Examination Guidelines at 60 FR 97 (Jan. 3, 1995)
APPENDIX H11.	Synopsis of Application of Utility Guidelines
APPENDIX H12.	House Report on Biotechnological Process Patents
APPENDIX H13.	Appropriations Bill (HR 3610) Containing Patent Limitations on Medical Procedures
APPENDIX H14.	Interim Examination Guidelines for Species Claims to Chemical Compositions Based Upon a Single Prior Art Reference (Feb. 13, 1997)
APPENDIX H15.	Training Materials for Examining Patent Applications with Respect to 35 USC 112 1st Paragraph—Enablement of Chemical/ Biotechnical Applications (1996)
APPENDIX H16.	PTO Final Rule for Submitting Nucleotide Sequences (Effective July 1, 1998)
APPENDIX H17.	Request for Comments on Interim Guidelines for Examination of Patent Applications under the 35 U.S.C. 112 para. 1 “Written Description” Requirement (June 15, 1998)
APPENDIX H18.	Request for Comments on the Revised Interim Guidelines for Examination of Patent Applications under the 35 U.S.C. 112 para. 1 “Written Description” Requirement (Dec. 21, 1999)
APPENDIX H19.	Revised Interim Written Description Guideline Training Materials
APPENDIX H20.	Revised Utility Examination Guidelines; Request for Comments
APPENDIX H21.	Revised Interim Utility Guidelines Training Materials

- APPENDIX H22. PTO Policy Statement on Genetic Inventions (Mar. 16, 2000)
- APPENDIX H23. Suggestions for the Resolution of Apparent Ambiguities Created by the Use of Percentage Sequence Identity Language in Claims
- APPENDIX H24. The Metes and Bounds of Claims Reciting Percent Sequence Similarity or Similar Language
- APPENDIX H25. Guidelines for Examination of Patent Applications Under the 35 U.S.C. 122, 1, “Written Description” Requirement (Jan. 5, 2001)
- APPENDIX H26. Utility Examination Guidelines (Jan. 5, 2001)
- APPENDIX H27. Examination of Patent Applications Containing Nucleotide Sequences

## **APPENDIX J—MISCELLANEOUS NON-U.S. MATERIALS**

- APPENDIX J1. European Patent Convention Article 53: Exceptions to Patentability
- APPENDIX J2. EPC Guidelines for Examination, Excerpts from Chapter II: Inventions Relating to Microorganisms (Guideline 6)
- APPENDIX J3. EPC Guidelines for Examination, Excerpts from Chapter IV, Plant and Animal Varieties Excluded from Patentability (Guidelines 3.4 and 3.5)
- APPENDIX J4. WIPO Standard ST.25
- APPENDIX J5. Trilateral Project 24.1: Biotechnology—Comparative Study on Biotechnology Patent Practices—Comparative Study Report

**Table of Cases**

**Index**